Dr. Harker-Murray is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9200 W Wisconsin Ave
# Division
Milwaukee, WI 53226Phone+1 414-805-6800Fax+1 414-805-0352
Education & Training
University of MinnesotaFellowship, Hematology and Medical Oncology, 2002 - 2005
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1999 - 2002- Mayo Clinic College of MedicineClass of 1999
Certifications & Licensure
WI State Medical License 2005 - 2025
TX State Medical License 2007 - 2014
MN State Medical License 2000 - 2011
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery Start of enrollment: 2013 Jul 31
- A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma Start of enrollment: 2015 Nov 23
- Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer Start of enrollment: 2019 May 17
Publications & Presentations
PubMed
- 74 citationsContinuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trialAlain Algazi, Megan Othus, Adil Daud, Roger S. Lo, Janice M. Mehnert
Nature Medicine. 2020-10-05 - 18 citationsLong-term prognosis of patients with clinical unstable angina pectoris without elevation of creatine kinase but with elevation of cardiac troponin i levels.Ronnier J. Aviles, R. Scott Wright, Jennifer M. Aviles, Furman S. McDonald, Karla V. Ballman
The American Journal of Cardiology. 2002-10-15 - 10 citationsDC-HIL+ CD14+ HLA-DR no/low cells are a potential blood marker and therapeutic target for melanoma.Jake E. Turrentine, Jin Sung Chung, Kaveh A. Nezafati, Kyoichi Tamura, Amy Harker-Murray
The Journal of Investigative Dermatology. 2014-11-01
Press Mentions
Family Inspired to Make a DifferenceJune 14th, 2022
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
